GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity

Starting soon

Conditions studied: Morbid Obesity, Anorectal Diseases, Drug-Related Side Effects and Adverse Reactions, Constipation, Diarrhea

In brief

Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.

Key facts

Study ID

NCT07668765

Run by

Gazi University

People needed

100

Starts

2026-08-01

Expected to finish

2027-05-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Morbid obesity (BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities)
• Newly prescribed GLP-1 receptor agonist therapy
• Ability and willingness to provide written informed consent
• Ability to attend 3-month follow-up visit

You may not qualify if…

• Inflammatory bowel disease
• Perianal Crohn's disease
• History of anorectal malignancy
• Previous pelvic radiotherapy
• Anorectal surgery within the previous 3 months
• Pregnancy
• Neurogenic bowel dysfunction
• Inability to comply with follow-up visits
• Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment
• Active anorectal infection or abscess

Where it is running

• Gazi University Faculty of Medicine — Ankara, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.